The global Continuous Glucose Monitoring (CGM) Sensors market size is predicted to grow from US$ 1892 million in 2025 to US$ 3345 million in 2031; it is expected to grow at a CAGR of 10.0% from 2025 to 2031.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets.

This Insight Report provides a comprehensive analysis of the global Continuous Glucose Monitoring (CGM) Sensors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.

Segmentation by Type:

• Noninvasive Sensing
• Minimally Invasive Sensing

Segmentation by Application:

• Home Care
• Hospital
• Others

Market by Region:

• Americas
• APAC
• Europe
• Middle East & Africa

Company's Coverage:

• Medtronics
• Abbott
• Senseonics
• WaveForm Technologies
• Echo Therapeutics Inc
• Arkal Medical
• Azurite Technologies
• Biorasis
• Calisto Medical
• DexCom Inc
• DirectSens GmbH
• EyeSense GmbH

Key Questions Addressed in this Report:

What is the 10-year outlook for the global Continuous Glucose Monitoring (CGM) Sensors market?